Principal Financial Group Inc. increased its holdings in Lantheus Holdings Inc (NASDAQ:LNTH) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 325,187 shares of the medical equipment provider’s stock after buying an additional 6,838 shares during the period. Principal Financial Group Inc. owned 0.83% of Lantheus worth $6,670,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Voya Investment Management LLC raised its position in Lantheus by 1,192.3% during the third quarter. Voya Investment Management LLC now owns 659,761 shares of the medical equipment provider’s stock valued at $16,537,000 after purchasing an additional 608,708 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in shares of Lantheus by 316.3% during the third quarter. Rice Hall James & Associates LLC now owns 422,540 shares of the medical equipment provider’s stock worth $10,591,000 after buying an additional 321,030 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Lantheus by 154.2% during the fourth quarter. Russell Investments Group Ltd. now owns 406,649 shares of the medical equipment provider’s stock worth $8,338,000 after buying an additional 246,695 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new stake in shares of Lantheus during the third quarter worth $2,075,000. Finally, First Trust Advisors LP bought a new stake in shares of Lantheus during the fourth quarter worth $1,337,000. Institutional investors own 98.28% of the company’s stock.
Shares of Lantheus stock traded down $0.05 during trading on Friday, hitting $15.59. The company’s stock had a trading volume of 12,824 shares, compared to its average volume of 346,403. The company has a debt-to-equity ratio of 1.60, a current ratio of 2.62 and a quick ratio of 2.08. Lantheus Holdings Inc has a 52 week low of $15.53 and a 52 week high of $29.80. The stock has a market cap of $639.82 million, a price-to-earnings ratio of 19.84 and a beta of 1.43. The stock has a 50-day moving average price of $17.61 and a two-hundred day moving average price of $20.39.
A number of research firms have weighed in on LNTH. ValuEngine raised shares of Lantheus from a “sell” rating to a “hold” rating in a research note on Saturday, February 15th. BidaskClub raised shares of Lantheus from a “strong sell” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Lantheus currently has a consensus rating of “Hold” and an average price target of $29.00.
In other Lantheus news, CEO Mary Anne Heino sold 9,898 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.06, for a total transaction of $158,961.88. Following the sale, the chief executive officer now owns 556,014 shares of the company’s stock, valued at $8,929,584.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 6,351 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $20.82, for a total transaction of $132,227.82. Following the sale, the chief financial officer now directly owns 53,428 shares in the company, valued at approximately $1,112,370.96. The disclosure for this sale can be found here. In the last three months, insiders sold 47,017 shares of company stock worth $926,373. 2.60% of the stock is currently owned by insiders.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
See Also: What does the Dogs of the Dow mean?
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.